

CP 1646

Docket No.: PF-0459 US #13

"Express Mail" mailing label number EL 473 912 361 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 15 June 2000

By:

Printed:

T. Martinez



RECEIVED
JUN 12 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title: HUMAN SIGNAL PEPTIDE-CONTAINING PROTEINS

Serial No.: 09/002,485

Filing Date: December 31, 1997

Examiner: Saoud, C.

Group Art Unit: 1646

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

The undersigned certifies in accordance with 37 C.F.R. §1.97(e)(2) that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

In view of the status of the subject application, pursuant to 37 CFR §1.97(c), Applicants hereby request consideration of this Information Disclosure Statement with Certification Under 37 C.F.R. §1.97(e)(2).

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.



Docket No.: PF-0459 US

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 C.F.R. §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-845-4892.

Respectfully submitted,
INCYTE GENOMICS, INC.

Date: 15 June 2000

Danielle M. Pasqualone
Danielle M. Pasqualone, Ph. D.
Reg. No. 43,847
Direct Dial Telephone: (650) 845-4892

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166